The current treatment algorithm for NSCLC is dominated by targeted branded therapies, reflecting its biomarker-driven treatment landscape. The EGFR and ALK TKIs Tagrisso and Alecensa have demonstrated significant survival improvements while the PD-1 / PD-L1 axis inhibitor Tecentriq in combination with chemotherapy has received regulatory approval for first-line metastatic nonsquamous NSCLC. In this dynamic scenario of rapidly evolving combinations of targeted and immunotherapy with chemotherapy, our primary research provides insight into the use of approved therapies for NSCLC in the United States and uncovers key factors that influence medical oncologists’ prescribing decisions.
- What are the treatment rates across the various lines of therapy in the metastatic NSCLC patient population?
- What is the uptake of Tecentriq plus chemotherapy in the first-line metastatic NSCLC setting, according to U.S. medical oncologists?
- How is new entrant Tagrisso performing in the face of existing EGFR inhibitors in the EGFR-mutation-positive metastatic NSCLC setting?
- What are the main obstacles to prescribing Tecentriq combinations as a first-line therapy for EGFR-mutation-positive NSCLC?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Geographies: United States
Primary Research: Survey of 101 medical oncologists in the United States
Key Drugs Covered: Keytruda, Opdivo, Tecentriq, Imfinzi, Tagrisso, Vizimpro, Avastin, Tarceva, Xalkori, Alecensa, Iressa, Gilotrif/ Giotrif
- Non-Small-Cell Lung Cancer - Current Treatment - Detailed, Expanded Analysis Physician Insights (US)
Author(s): Snigdha Gupta, Ph.D; Joshua Dawkins, M.Pharmacol., PhD
Dr. Snigdha Gupta is a Lead Analyst in the oncology team at Decision Resources Group with expertise in multiple oncology indications including non-small cell lung cancer and multiple myeloma.
Prior to joining DRG, Dr. Snigdha Gupta was a subject matter expert in immune-oncology, autoimmunity and dealt in generating in-depth framework based scientific analyses for client projects. In her previous organizations, she was involved in the planning and execution of the IND enabling preclinical studies. She has been instrumental in the stage-up of two small molecules at Bioxcel Therapeutics and Daiichi Sankyo Pharma India Pvt. Ltd. Dr. Gupta holds Ph.D. in infectious diseases from the Indian Institute of Chemical Biology, Jadavpur University, Kolkata while her post-doctoral fellowship is from the Mucosal immunology labs of National Institute of Immunology, New Delhi.
Joshua Dawkins, M.Pharmacol., Ph.D., is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Dawkins obtained his doctorate in molecular biology at the Barts Cancer Institute, Queen Mary University of London, where he investigated the roles of epigenetic histone modifiers in pancreatic ductal adenocarcinoma. Dr. Dawkins also holds a Master of Pharmacology degree awarded by the University of Bath, and completed a one-year professional placement within the oncology team at MedImmune.